What is the role of lenvatinib (Lenvima) in the treatment of renal cell carcinoma (RCC)?

Updated: Feb 19, 2021
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print

In 2016, the FDA approved lenvatinib (Lenvima) in combination with everolimus for advanced RCC following 1 prior antiangiogenic therapy. Approval was based on a randomized, phase II open-label, multicenter trial of 153 patients with advanced clear-cell RCC who had progressed on or within 9 months of stopping VEGF receptor–targeted therapy. Progression-free survival (PFS) was significantly improved with lenvatinib in combination with everolimus compared with everolimus alone (14.5 mo vs 5.5 mo; P=0.0005).  When the 2 monotherapies were analyzed, there was a modest improvement in PFS with lenvatinib 7.4 months (P=0.048). [44]

Lenvatinib is a small molecule tyrosine kinase (TK) inhibitor that inhibits the kinase activities of VEGF receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). It also inhibits other TKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular function.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!